There is increasing evidence that dihydroorotate dehydrogenase (DHODH), an essential enzyme for de novo pyrimidine synthesis, is a promising therapeutic target in various cancer types, including melanoma, acute myeloid leukemia, glioblastoma, lung cancer, pancreatic cancer, and prostate cancer (20–25). Here, DHODH is linked to prostate carcinoma.